Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
2005 1
2006 1
2007 7
2008 3
2009 4
2010 2
2011 4
2012 6
2013 8
2014 11
2015 11
2016 19
2017 28
2018 30
2019 23
2020 27
2021 26
2022 18
2023 15
2024 17
2025 24

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

247 results

Results by year

Filters applied: . Clear all
Page 1
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
Zlotta AR, Ballas LK, Niemierko A, Lajkosz K, Kuk C, Miranda G, Drumm M, Mari A, Thio E, Fleshner NE, Kulkarni GS, Jewett MAS, Bristow RG, Catton C, Berlin A, Sridhar SS, Schuckman A, Feldman AS, Wszolek M, Dahl DM, Lee RJ, Saylor PJ, Michaelson MD, Miyamoto DT, Zietman A, Shipley W, Chung P, Daneshmand S, Efstathiou JA. Zlotta AR, et al. Among authors: kulkarni gs. Lancet Oncol. 2023 Jun;24(6):669-681. doi: 10.1016/S1470-2045(23)00170-5. Epub 2023 May 12. Lancet Oncol. 2023. PMID: 37187202
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.
Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguié M, Krieger LEM, Singer EA, Bajorin DF, Grivas P, Seo HK, Nishiyama H, Konety BR, Li H, Nam K, Kapadia E, Frenkl T, de Wit R. Balar AV, et al. Among authors: kulkarni gs. Lancet Oncol. 2021 Jul;22(7):919-930. doi: 10.1016/S1470-2045(21)00147-9. Epub 2021 May 26. Lancet Oncol. 2021. PMID: 34051177 Clinical Trial.
Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial.
Necchi A, Roumiguié M, Kamat AM, Shore ND, Boormans JL, Esen AA, Lebret T, Kandori S, Bajorin DF, Krieger LEM, Niglio SA, Uchio EM, Seo HK, de Wit R, Singer EA, Grivas P, Nishiyama H, Li H, Baranwal P, Van den Sigtenhorst-Fijlstra M, Kapadia E, Kulkarni GS. Necchi A, et al. Among authors: kulkarni gs. Lancet Oncol. 2024 Jun;25(6):720-730. doi: 10.1016/S1470-2045(24)00178-5. Epub 2024 May 10. Lancet Oncol. 2024. PMID: 38740030 Clinical Trial.
Reply by Authors.
Murayama A, Nguyen DD, Nguyen AV, Murad L, Cheng A, Elterman DS, Kulkarni GS, Bhojani N, Satkunasivam R, Trinh QD, Marshall DC, Wallis CJD. Murayama A, et al. Among authors: kulkarni gs. Urol Pract. 2025 Mar;12(2):290. doi: 10.1097/UPJ.0000000000000753. Epub 2025 Feb 21. Urol Pract. 2025. PMID: 39981957 No abstract available.
Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.
Shore ND, Powles TB, Bedke J, Galsky MD, Palou Redorta J, Ku JH, Kretkowski M, Xylinas E, Alekseev B, Ye D, Guerrero-Ramos F, Briganti A, Kulkarni GS, Brinkmann J, Calella AM, Cesari R, Eccleston A, Michelon E, Vermette J, Wei C, Steinberg GD. Shore ND, et al. Among authors: kulkarni gs. Nat Med. 2025 Aug;31(8):2806-2814. doi: 10.1038/s41591-025-03738-z. Epub 2025 May 31. Nat Med. 2025. PMID: 40450141 Free PMC article. Clinical Trial.
Radical cystectomy-what is the optimal surgical approach?
Nason GJ, Ajib K, Tan GH, Kulkarni GS. Nason GJ, et al. Among authors: kulkarni gs. Transl Androl Urol. 2020 Oct;9(5):2308-2312. doi: 10.21037/tau-20-880. Transl Androl Urol. 2020. PMID: 33209702 Free PMC article. No abstract available.
Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial.
Fleshner NE, Sayyid RK, Hansen AR, Chin JLK, Fernandes R, Winquist E, van der Kwast T, Sweet J, Lajkosz K, Kenk M, Hersey K, Veloso R, Berlin D, Herrera-Caceres JO, Sridhar S, Moussa M, Finelli A, Hamilton RJ, Kulkarni GS, Zlotta AR, Joshua AM. Fleshner NE, et al. Among authors: kulkarni gs. Clin Cancer Res. 2023 Oct 2;29(19):3867-3874. doi: 10.1158/1078-0432.CCR-23-0731. Clin Cancer Res. 2023. PMID: 37439809 Clinical Trial.
Reply by Authors.
Richard PO, Bashir S, Riverin BD, Alibhai SMH, Kim SJ, Ahmad A, Fleshner NE, Gupta A, Mohammed A, Zlotta AR, Kulkarni GS. Richard PO, et al. Among authors: kulkarni gs. J Urol. 2019 Aug;202(2):325. doi: 10.1097/01.JU.0000558494.56102.db. Epub 2019 Jul 8. J Urol. 2019. PMID: 31042130 No abstract available.
Proportion of Gleason Score ≥8 Prostate Cancer on Biopsy and Tumor Aggressiveness in Matched Cohorts of East Asian and Non-East Asian Men.
Dong L, Lajkosz K, Sanchez-Salas R, Kuk C, Xu W, Tiwari RV, Dias Dos Santos CP, Qian H, Wang J, Dong B, Pan J, Zhu Y, Liu Q, Chan A, Kwong JCC, Woon DTS, Nesbitt M, Erlich A, Kulkarni GS, Perlis N, Hamilton RJ, Klotz L, Wallis CJD, Nguyen DD, Macek P, Tay KJ, Huang H, Toi A, Finelli A, Fleshner NE, Cheng CWS, Cathelineau X, van der Kwast TH, Xue W, Zlotta AR. Dong L, et al. Among authors: kulkarni gs. J Natl Compr Canc Netw. 2024 Nov 15;22(10):e247061. doi: 10.6004/jnccn.2024.7061. J Natl Compr Canc Netw. 2024. PMID: 39546889
247 results